SVF
Level C· Early human research exploring benefitsProspective StudyPubMed

Type 2 Diabetes-Induced Molecular and Functional Impairment of Adipose Tissue-Derived Mesenchymal Stromal Cells (ASCs) and Interferon Gamma Priming for Enhanced Diabetic ASC-Based Therapy.

Zeinhom A., Mohamed AY., Abdel-Aziz NN., Sayed Diab M., Salem AMH., Yassen NN.

Prospective Study on Type 2 Diabetes, Chronic Inflammation, Immune Modulation, published in Stem Cell Rev Rep (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Stem Cell Rev Rep (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
42240955
DOI
10.1007/s12015-026-11164-y

Abstract (original English)

Background Transplantation of adipose-derived mesenchymal stromal cells (ASCs) or their insulin-producing derivatives holds promise for diabetes mellitus therapy due to their regenerative properties. However, the harsh microenvironment in type 2 diabetes (T2D) likely impairs autologous ASC efficacy. Aim This study investigated transcriptomic alterations and therapeutic efficacy of ASCs from T2D patients (dASCs) in experimental diabetes, compared to healthy donors (ndASCs), and evaluated whether inflammatory priming could enhance dASC functionality. Methods dASCs and ndASCs were characterized phenotypically and functionally. Differentially expressed genes (DEGs) were identified via microarray profiling of basal and IFN-γ/TNF-α-primed cells. miRNA-transcription factor (TF) coregulatory networks were constructed for key DEGs. In vivo, anti-hyperglycemic effects, islet regeneration, insulin expression, and local inflammation modulation were assessed in streptozotocin (STZ)-induced diabetic rats by transplanting dASCs, ndASCs, or IFN-γ-primed dASCs (p.dASCs). Results DEGs in dASCs were significantly enriched in inflammation, glycerolipid metabolism, cell adhesion, cytoskeleton remodeling, angiogenesis, and insulin or hypoxia-related responses. EGFR/ERBB2 signaling, with downstream Ras/MAPK and PI3K/AKT cascades, and endocrine resistance-related pathways were significantly overrepres

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AnimalsMesenchymal Stem CellsDiabetes Mellitus, Type 2Interferon-gammaAdipose TissueRatsHumansDiabetes Mellitus, ExperimentalMesenchymal Stem Cell TransplantationMale
Face & SkinSystemic / IVType 2 DiabetesChronic InflammationImmune Modulation
View on PubMedDOI

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

View all: topic “type diabetes-induced molecular”View all: author zeinhomView all: year 2026

Related research